Key Pillar of a Successful CDMO: Exceptional Regulatory Compliance
Jagjyot (Jot) Kaur, Market Intelligence Manager
Ensuring regulatory compliance is paramount for a CDMO to meet manufacturing standards, warrant patient safety, and maintain its reputation. As we know, the pharma industry is heavily regulated, and CDMOs must adhere to all regulatory frameworks, such as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Laboratory Practice (GLP). It is pivotal to understand the landscape to navigate the compliance requirements effectively.
Balancing regulatory commitment is imperative to assure pharma clients who rely on CDMOs to deliver safe and effective drugs. It gives them confidence that their products are being developed and manufactured following industry standards, thereby enhancing trust and fostering long-term partnerships. One vital component of the process is that regulatory fulfillment is not a one-time achievement but an ongoing initiative. CDMOs are expected to remain current while continuously monitoring and updating their compliance practices. Maintaining high-quality standards throughout the drug development and manufacturing process minimizes the risk of contamination, adulteration, or other concerns.
Speed to Market:
With the current tight market conditions, API shortages, supply chain issues, and high demand for critical drugs, regulatory agencies are supporting companies to deliver at speed via fast track, breakthrough therapy, priority reviews, etc. And though these programs shorten the drug-to-market timeline, if regulatory requirements are overlooked, it brings enormous risk and catastrophic delays; worse, the drug might not get approval at all, or a CDMO loses the right to manufacture. Companies often make errors due to the pressure to bring the drug to market at an accelerated speed. To overcome this, adhering to uncompromised quality and having a clear set of procedures and reliable manufacturing processes to assess the timelines and speed to operate are essential.
What happens when a CDMO fails to comply?
Any experienced CDMO has a good understanding of what will and will not align with requirements set forth by the FDA. Cutting corners without understanding its consequences can bring tremendous harm in the long term, which could include unnecessary financial obligations, product recalls, regulatory penalties, legal actions, or criminal prosecutions. All of this is avoidable if CDMOs identify and mitigate potential risks early on, guaranteeing smooth operations and minimizing the likelihood of breaches. Open lines of communication between the customer and CDMO help build trust. Regular audits, training programs, and quality management systems are essential for maintaining fulfillment.
Another crucial factor in this system is data integrity and documentation. If a CDMO establishes robust data management systems, ensuring confidentiality, traceability, as well as proper documentation of processes, procedures, and quality control measures, it becomes a smooth path forward while demonstrating compliance during regulatory inspections.
Regulatory commitment is one of the pillars on which a CDMO survives. One way to ensure that a 483 doesn’t show up is by familiarizing yourself with common compliance issues and focusing on those areas. I’ll also add that collaboration with regulatory authorities, such as the FDA, helps CDMOs maintain open channels of communication and stay updated on any changes. Proactive engagement with regulators helps CDMOs align their practices as expected. They can seek guidance when needed and ensure a smooth regulatory approval process for clients. Whether it’s quality, safety, adherence to industry standards, or client trust, it all hedges on your strong regulatory background. By prioritizing compliance management, a CDMO can mitigate risk factors and maintain a competitive edge in the pharmaceutical and biotechnology industry.
Societal CDMO as your partner:
Societal specializes in helping U.S. and foreign companies through the FDA regulatory process, including:
- Assistance with end-to-end filing strategies (e.g., IND, NDA, ANDA, 505 (b)(1), 505 (b)(2), NDS), including for global markets (e.g., ROW submissions) and specialty designations (e.g., orphan drug)
- Early-stage guidance
- CMC authoring support
- Late-phase/NDA consultation
- Planning and preparation of regulatory documentation (eCTD submission-ready)
- Provide support for responding to FDA questions during the review process
- FDA meeting guidance and support
- Pre-IND (briefing document preparation and submission/formulation development questions for the FDA)
- End-of-phase 2
- Post-approval product management
- Pharmacovigilance surveillance/reporting guidance
Societal has a thorough understanding of current regulatory philosophy and standards, as well as direct experience in working with the FDA at all levels. Our history as a successful drug development and commercial pharma company spans a wide range of therapeutic categories, including anti-viral, neurology, oncology, gastroenterology, and CNS. We can also collaborate with your existing regulatory department or provide your organization with independent regulatory affairs support, thereby serving as your development partner from planning for your initial FDA meeting to the commercialization of your product.
To learn how Societal can help with your next project, contact us here.